ClinicalTrials.gg

Program

MK-8690

A development code. Also written as “PRA052”.

Its studies are mostly in Colitis, Ulcerative · Arthritis, Rheumatoid, led by Merck.

Furthest: phase 2, since Mar 4, 20263 company-led studies, 2 open or runningNext primary completion: Oct 19, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck32 open or runningphase 2since Mar 4, 2026Oct 27, 2022Oct 19, 2027phase 2 · NCT07895524
  • Named in Merck’s own pipeline as MK-8690, phase 2, as of Nov 2, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 27, 2022First study: phase 1 study in HealthyFirst studyNCT05603182 · 96 enrolled · United States
  2. Mar 4, 2026Phase 2 study in Colitis, UlcerativePhase 2 reachedNCT07463183 · 100 planned · United States, Canada, Chile and more
  3. Oct 19, 2026Phase 2 study in Arthritis, RheumatoidNCT07895524 · 60 planned

Ahead

  1. Oct 19, 2027Primary completion: phase 2 study in Arthritis, RheumatoidNCT07895524
  2. Oct 28, 2027Primary completion: phase 2 study in Colitis, UlcerativeNCT07463183

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07895524Arthritis, Rheumatoid2Not yet recruitingOct 19, 202760
NCT07463183Colitis, Ulcerative · United States, Canada, Chile and more2RecruitingOct 28, 2027100
NCT05603182Healthy · United States1CompletedFeb 21, 202496

How it is read

Names in the registry

  • “MK-8690”, 2 entries
  • “PRA052”, 1 entry

Codes read as this program: MK8690, PRA052.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.